Suchergebnisse - "Brunetti, Oronzo"

PubPharm (9)

1

Impact of COVID-19 pandemic on outpatient visit volume in cancer patients : Results of COMETA multicenter retrospective observational study

enthalten in: Frontiers in public health | 2023

von Frisardi, V. | Brunetti, O. | Abbinante, V. | +15

2

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

enthalten in: Targeted oncology | 2020

von Orsi, G. | Tovoli, F. | Dadduzio, V. | +23

ErratumIn: Target Oncol. 2020 Oct 28;:. - PMID 33113041

3

The Italian Rare Pancreatic Exocrine Cancer Initiative

enthalten in: Tumori | 2019

von Brunetti, O. | Luchini, C. | Argentiero, A. | +26

ErratumIn: Tumori. 2020 Dec;106(6):526. - PMID 32172676

4

Prediction of survival with second-line therapy in biliary tract cancer : Actualisation of the AGEO CT2BIL cohort and European multicentre validations

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Neuzillet, C. | Casadei Gardini, A. | Brieau, B. | +56

5

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol

enthalten in: Tumori | 2018

von Gardini, A. | Faloppi, L. | Aprile, G. | +29

6

Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors : A Retrospective Multicenter Analysis

enthalten in: Pancreas | 2018

von Brunetti, O. | Aprile, G. | Marchetti, P. | +20

7

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib : Validation study and biological rationale

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Casadei Gardini, A. | Faloppi, L. | De Matteis, S. | +19

8

Selecting patients for gastrectomy in metastatic esophago-gastric cancer : clinics and pathology are not enough

enthalten in: Future oncology (London, England) | 2017

von Fornaro, L. | Fanotto, V. | Musettini, G. | +24

ErratumIn: Future Oncol. 2018 Mar;14 (6):577. - PMID 29441800

9

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma : a retrospective study

enthalten in: Scientific reports | 2017

von Casadei Gardini, A. | Foca, F. | Scartozzi, M. | +13

1
[1]